摘要
背景:课题组在国内首次合成了葡萄球菌抑制剂RNAⅢ抑制肽,并制备了RNAⅢ抑制肽/磷酸胆碱基细胞膜仿生药物涂层。目的:评价RNAⅢ抑制肽/磷酸胆碱基细胞膜仿生药物涂层的血液相容性。设计、时间及地点:随机对照动物实验,于2005-10/2007-10在解放军总医院临床药理研究所及医学动物实验中心完成。材料:成年普通级健康新西兰大白兔30只,由解放军总医院动物实验中心提供。方法:将洁净的316L不锈钢片浸渍于5g/L的四元共聚物四氢呋喃和质量分数10%的RNAⅢ抑制肽混合溶液中,获得稳定的聚合物涂层,按1cm2/mL在37℃无菌条件下用生理盐水浸提72h,制得浸提液原液;加入同体积的无菌生理盐水制得50%浸提液。选择溶血实验、凝血实验、血小板聚集实验,测定凝血酶原时间和活化部分凝血酶时间、观察RNAⅢ抑制肽/磷酸胆碱基细胞膜仿生药物涂层对兔白细胞、红细胞和血小板的影响。主要观察指标:红细胞溶血率,凝血时间、凝血酶原时间、活化部分凝血酶时间,白细胞、红细胞和血小板数量,血小板聚集情况。结果:溶血实验结果显示浸提液原液和50%浓度浸提液的溶血率分别为3.08%和1.88%,两者的溶血率均<5%,符合医用生物材料的溶血实验要求。凝血实验结果表明浸提液原液和50%浓度浸提液对兔凝血时间无明显影响,对各时间点兔凝血酶原时间和活化部分凝血酶时间均无明显作用,对兔白细胞、红细胞和血小板数量无明显影响,对兔血小板聚集无明显影响。结论:实验数据表明,国内首次合成的RNAⅢ抑制肽/磷酸胆碱基细胞膜仿生药物涂层具有良好的血液相容性。
BACKGROUND: Staphylococci inhibitor, RNAIII inhibiting peptide, has been firstly synthesized in China, while RNAIII inhibiting peptide/bioinspired phosphorylcholine-based cytomembrane coating (RIP/PC) has been also prepared. OBJECTIVE: To evaluate the blood compatibility of RIP/PC. DESIGN, TIME AND SETTING: A randomized controlled animal experiment was performed at Institute of Clinical Pharmacologic Research and Medical Animal Experimental Center of General Hospital of Chinese PLA from October 2005 to October 2007. MATERIALS: A total of 30 healthy adult New Zealand rabbits were provided by Animal Experimental Center of General Hospital of Chinese PLA. METHODS: The 316L stainless steel was dip into a mixture of 5 g/L quaternionic copolymer tetrahydrofuran and 10% RNAIII inhibiting peptide to obtain stable polymer coating, which was extracted at density of 1 cm2/mL in saline at 37 ~C for 72 hours to get 100% eluent. The same volume of saline was added to make 50% eluent. The effects of RIP/PC on leukocytes, erythrocytes, and blood platelet of rabbits were detected via measuring prothrombin time and activated thrombin time during hemolysis test, hemagglutinatin test, and blood platelet aggregation test. MAIN OUTCOME MEASURES: Hemolytic ratio of erythrocytes, clotting time, prothrombin time, activated thrombin time, amounts of leukocytes, erythrocytes, and blood platelet, as well as blood platelet aggregation. RESULTS: Hemolysis test showed that the hemolytic ratio was 3.08% and 1.88% of 100% and 50% eluent, respectively; both the hemolytic ratios were 〈 5%, suggesting being coincidence with hemolytic requests of biological materials. The hemagglutinatin test showed that both 100% and 50% eluent did not have any effect on clotting time, prothrombin time, activated thrombin time, amounts of leukocytes, erythrocytes, and blood platelet, as well as blood platelet aggregation. CONCLUSION: The firstly synthesized RIP/PC has a good biocompatibility.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2009年第47期9385-9388,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
基金
the National Natural Science Foundation of China, No. 30640088~~